A Phase I/II, Randomized, Placebo-controlled Comparative Study to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Bone Marrow (BM) Derived MSCs to Evaluate Cytokine Suppression in Patients With Chronic Inflammation Due to Metabolic Syndrome.
Trial Snapshot
- Phase
- Phase 1
- Status
- Terminated
- Sponsor
- Enrollment
- 14
- Locations
- 1
- Primary Endpoint
- Number of Treatment-Emergent Serious Adverse Events (TE-SAEs)
Study Overview
Brief Summary
This study is to compare the safety and efficacy of UCMSCs and BMMSCs administered intravenously in patients to evaluate cytokine suppression in patients with chronic inflammation. Cells administered via intravenous infusion (IV) and will be tested in 37 patients in two phases (Pilot and Randomized).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description
Pilot phase is open-label. Randomized phase is blinded.
Eligibility Criteria
- Ages
- 21 Years to 95 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Provide written informed consent
- •Subjects age > 21 and < 95 years at the time of signing the Informed Consent Form.
- •Each subject must have endothelial dysfunction.
- •Endothelial dysfunction Criteria:
- •Impaired flow-mediated vasodilation (FMD <7%)
- •At the time of enrollment, each subject must meet at least 3 out of the 5 criteria under the harmonized definition of the metabolic syndrome, consisting of the following:
- •Waist circumference - US defined: ≥ 102 cm (males) or ≥ 88 cm (females)
- •Elevated triglycerides - ≥ 150 mg/dL (1.7 mM)
- •Reduced HDL-C - Males: <40 mg/dL (1.0 mM) Females: <50 mg/dL (1.3 mM)
- •Elevated blood pressure - Systolic ≥ 130 mm Hg and/or Diastolic ≥ 85 mm Hg
- •Elevated fasting glucose - ≥ 100 mg/dL
Exclusion Criteria
- •Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female subjects must undergo a blood or urine pregnancy test at screening and within 36 hours prior to infusion.
- •Inability to perform any of the assessments required for endpoint analysis.
- •Active listing (or expected future listing) for transplant of any organ.
- •Clinically important abnormal screening laboratory values, as determined by the P.I.
- •Serious comorbid illness or any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study.
- •Have known allergies to penicillin or streptomycin.
- •Hypersensitivity to dimethyl sulfoxide (DMSO).
- •Be a solid organ transplant recipient. This does not include prior cell-based therapy (>12 months prior enrollment) bone, skin, ligament, tendon or corneal grafting. Have a history of organ or cell transplant rejection.
- •Have a clinical history of malignancy within 3 years (i.e., subjects with prior malignancy must be disease free for 3 years), except curatively- treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ or cervical carcinoma, if recurrence occurs.
- •Have a non-pulmonary condition that limits lifespan to < 1 year.
- •History of drug abuse (illegal "street" drugs except marijuana, or prescription medications not being used appropriately for a pre-existing medical condition) or alcohol abuse (≥ 5 drinks/day for ˃ 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs within the past 24 months.
- •Be serum positive for HIV, hepatitis B surface antigen or Viremic hepatitis C, and/or Syphilis.
- •Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.
- •Patients with Ejection Fraction <45% (heart failure patients).
- •Glomerular Filtration Rate < or equal to 35 (chronic kidney disease stage 3 or higher).
- •Liver disease (elevated Liver Function Tests greater than 3x normal limit).
- •Advanced pulmonary disease (requiring home oxygen and/or less than 1 expected life span).
- •Proliferative diabetic retinopathy
- •Hemoglobin A1C greater than 7.
Arms & Interventions
Pilot Phase: Group 1 (UCMSCs - 20 million)
Three (3) subjects will be treated with a single administration of 2 x 10^7 (20 million) UCMSCs delivered via peripheral intravenous infusion.
Intervention: UCMSCs (Biological)
Pilot Phase: Group 3 (UCMSCs - 100 million)
Three (3) subjects will be treated with a single IV administration of 1 x 10^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.
Intervention: UCMSCs (Biological)
Pilot Phase: Group 2 (BMMSCs - 20 million)
Three (3) subjects will be treated with a single IV administration of 2 x 10^7 (20 million) BMMSCs delivered via peripheral intravenous infusion.
Intervention: BMMSCs (Biological)
Pilot Phase: Group 4 (BMMSCs -100 million)
Three (3) subjects will be treated with a single IV administration of 1 x 10^8 (100 million) BMMSCs delivered via peripheral intravenous infusion.
Intervention: BMMSCs (Biological)
Group A (UCMSCs - 100 million)
Participants randomized to receive a single administration of 1 x 10^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.
Intervention: UCMSCs (Biological)
Group B (BMMSCs - 100 million)
Participants randomized to receive a single administration of 1 x 10^8 (100 million) BMMSC delivered via peripheral intravenous infusion.
Intervention: BMMSCs (Biological)
Group C (Placebo)
Participants randomized to receive a single administration of placebo via peripheral intravenous infusion.
Intervention: Placebo (Other)
Outcomes
Primary Outcomes
Number of Treatment-Emergent Serious Adverse Events (TE-SAEs)
Time Frame: one month post infusion
Number of treatment-emergent serious adverse events (SAE) (at one-month post infusion), defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities, determined per the Investigator's judgment.
Secondary Outcomes
- Endothelial Progenitor Cell-Colony Forming Units (EPC-CFUs)(at Baseline, and at 3 months)
- hsCRP Levels(at Baseline, at Week 2, at Month 1, at Month 3, and at Month 6)
- Stem Cell Factor (SCF) Levels(at Baseline, at Week 2, at Month 1, at Month 3, and at Month 6)
- Cytokine Levels(at Baseline, at Week 2, at Month 1, at Month 3, and at Month 6)
- Flow Mediated Diameter Percentage (FMD%)(at Baseline and at Month 3)
Investigators
Joshua M Hare
Director of ISCI, Louis Lemberg Professor of Medicine
University of Miami